NPRL2 enhances autophagy and the resistance to Everolimus in castration-resistant prostate cancer.

Zhixiong ChenQilong JiangPingyu ZhuYanlin ChenXuemei XieZhongbo DuLi JiangWei Tang

Published in: The Prostate (2018)

NPRL2 may act as a pro-growth factor in PCa. The high levels of NPRL2 expression in CRPC promote resistance to EVS by enhancing autophagy. NPRL2 may be a new therapeutic target for intervention of CRPC and a biomarker for predicting resistance to EVS in CRPC.

Keyphrases

growth factor
cell death
endoplasmic reticulum stress
randomized controlled trial
signaling pathway
oxidative stress
poor prognosis